Table Filtering
Other Information
Release Statistics Download
GlyCosmos Glycolipids

Glycolipid entries from the LIPID MAPS Structure Database (LMSD).

Source Last Updated
LIPID MAPS Proteome Database (LMSD) June 16, 2024
Displaying entries 1126 - 1150 of 3913 in total
Main Class Sub Class LM ID Name LipidBank ID KEGG ID PubChem CID ChEBI ID Exact Mass ▲ Formula
Neutral glycosphingolipids Galalpha1-4Galbeta1-4Glc- (Globo series) LMSP0502AI07
  • Fucalpha1-2Galbeta1-3GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/24:1(15Z))
  • type IV H(d18:1/24:1(15Z))
44260234 1644.970228 C80H144N2O32
Neutral glycosphingolipids Galalpha1-4Galbeta1-4Glc- (Globo series) LMSP0502BM07
  • Fucalpha2-3Galbeta1-3GalNAcbeta1-4Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/24:1(15Z))
44260474 1644.970228 C80H144N2O32
Neutral glycosphingolipids GalNAcbeta1-4Galbeta1-4Glc- (Ganglio series) LMSP0503AK07
  • Galalpha1-3(Fucalpha1-2)Galbeta1-3GalNAcbeta1-4Galbeta1-4Glcbeta-Cer(d18:1/24:1(15Z))
44260570 1644.970228 C80H144N2O32
Neutral glycosphingolipids Galbeta1-3GlcNAcbeta1-3Galbeta1-4Glc- (Lacto series) LMSP0504AE07
  • Galalpha1-3(Fucalpha1-2)Galbeta1-3GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/24:1(15Z))
  • type I B antigen(d18:1/24:1(15Z))
44260650 1644.970228 C80H144N2O32
Neutral glycosphingolipids Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) LMSP0505AE07
  • Galalpha1-3(Fucalpha1-2)Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/24:1(15Z))
  • type II B antigen(d18:1/24:1(15Z))
44261010 1644.970228 C80H144N2O32
Neutral glycosphingolipids Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) LMSP0505CV07
  • Gala 1-3Lex(d18:1/24:1(15Z))
  • Galalpha1-3Galbeta1-4(Fucalpha1-3)GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/24:1(15Z))
44261554 1644.970228 C80H144N2O32
Neutral glycosphingolipids Galalpha1-3Galbeta1-4Glc- (Isoglobo series) LMSP0506AW07
  • Galbeta1-4(Fucalpha1-3)GlcNAcbeta1-3Galalpha1-3Galbeta1-4Glcbeta-Cer(d18:1/24:1(15Z))
44261618 1644.970228 C80H144N2O32
Neutral glycosphingolipids Galalpha1-3Galbeta1-4Glc- (Isoglobo series) LMSP0506BB07
  • Fucalpha1-2Galbeta1-3GalNAcbeta1-3Galalpha1-3Galbeta1-4Glcbeta-Cer(d18:1/24:1(15Z))
44261642 1644.970228 C80H144N2O32
Acidic glycosphingolipids Gangliosides LMSP0601BY05
  • NeuGcalpha2-3Galbeta1-3GalNAcbeta1-4Galbeta1-4Glcbeta-Cer(d18:1/24:0)
44262368 1645.965477 C79H143N3O32
Acidic glycosphingolipids Gangliosides LMSP0601CJ05
  • Galbeta1-3GalNAcbeta1-4(NeuGcalpha2-3)Galbeta1-4Glcbeta-Cer(d18:1/24:0)
44262440 1645.965477 C79H143N3O32
Acidic glycosphingolipids Gangliosides LMSP0601FF05
  • NeuGcalpha2-3Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/24:0)
44262984 1645.965477 C79H143N3O32
Acidic glycosphingolipids Gangliosides LMSP0601AN01
  • GD2(d18:1/16:0)
  • GalNAcbeta1-4(NeuAcalpha2-8NeuAcalpha2-3)Galbeta1-4Glcbeta-Cer(d18:1/16:0)
44262068 1646.887956 C76H134N4O34
Neutral glycosphingolipids Galalpha1-4Galbeta1-4Glc- (Globo series) LMSP0502AI05
  • Fucalpha1-2Galbeta1-3GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/24:0)
  • type IV H(d18:1/24:0)
44260232 1646.985878 C80H146N2O32
Neutral glycosphingolipids Galalpha1-4Galbeta1-4Glc- (Globo series) LMSP0502BM05
  • Fucalpha2-3Galbeta1-3GalNAcbeta1-4Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/24:0)
44260472 1646.985878 C80H146N2O32
Neutral glycosphingolipids GalNAcbeta1-4Galbeta1-4Glc- (Ganglio series) LMSP0503AK05
  • Galalpha1-3(Fucalpha1-2)Galbeta1-3GalNAcbeta1-4Galbeta1-4Glcbeta-Cer(d18:1/24:0)
44260568 1646.985878 C80H146N2O32
Neutral glycosphingolipids Galbeta1-3GlcNAcbeta1-3Galbeta1-4Glc- (Lacto series) LMSP0504AE05
  • Galalpha1-3(Fucalpha1-2)Galbeta1-3GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/24:0)
  • type I B antigen(d18:1/24:0)
44260648 1646.985878 C80H146N2O32
Neutral glycosphingolipids Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) LMSP0505AE05
  • Galalpha1-3(Fucalpha1-2)Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/24:0)
  • type II B antigen(d18:1/24:0)
44261008 1646.985878 C80H146N2O32
Neutral glycosphingolipids Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) LMSP0505CV05
  • Gala 1-3Lex(d18:1/24:0)
  • Galalpha1-3Galbeta1-4(Fucalpha1-3)GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/24:0)
44261552 1646.985878 C80H146N2O32
Neutral glycosphingolipids Galalpha1-3Galbeta1-4Glc- (Isoglobo series) LMSP0506AW05
  • Galbeta1-4(Fucalpha1-3)GlcNAcbeta1-3Galalpha1-3Galbeta1-4Glcbeta-Cer(d18:1/24:0)
44261616 1646.985878 C80H146N2O32
Neutral glycosphingolipids Galalpha1-3Galbeta1-4Glc- (Isoglobo series) LMSP0506BB05
  • Fucalpha1-2Galbeta1-3GalNAcbeta1-3Galalpha1-3Galbeta1-4Glcbeta-Cer(d18:1/24:0)
44261640 1646.985878 C80H146N2O32
Neutral glycosphingolipids Galalpha1-4Galbeta1-4Glc- (Globo series) LMSP0502AF03
  • Galbeta1-3(GlcNAcbeta1-6)GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/20:0)
44260206 1647.944742 C78H141N3O33
Neutral glycosphingolipids Galalpha1-4Galbeta1-4Glc- (Globo series) LMSP0502BE03
  • GalNAcalpha1-3Galbeta1-3GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/20:0)
44260406 1647.944742 C78H141N3O33
Neutral glycosphingolipids Galalpha1-4Galbeta1-4Glc- (Globo series) LMSP0502BG03
  • Galbeta1-4GlcNAcbeta1-6GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/20:0)
44260422 1647.944742 C78H141N3O33
Neutral glycosphingolipids Galalpha1-4Galbeta1-4Glc- (Globo series) LMSP0502BL03
  • GalNAcbeta1-3(Galbeta1-3GalNAcbeta1-4)Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/20:0)
44260462 1647.944742 C78H141N3O33
Neutral glycosphingolipids GalNAcbeta1-4Galbeta1-4Glc- (Ganglio series) LMSP0503AD03
  • Galbeta1-4GalNAcbeta1-3Galbeta1-3GalNAcbeta1-4Galbeta1-4Glcbeta-Cer(d18:1/20:0)
44260510 1647.944742 C78H141N3O33

About Release Notes Help Feedback

Click here to visit the beta site.


International Collaboration

GlyCosmos is a member of the GlySpace Alliance together with GlyGen and Glycomics@ExPASy.

Acknowledgements

Supported by JST NBDC Grant Number JPMJND2204

Partly supported by NIH Common Fund Grant #1U01GM125267-01


Logo License Policies Site Map

Contact: support@glycosmos.org

This work is licensed under Creative Commons Attribution 4.0 International


GlyCosmos Portal v4.0.0

Last updated: August 19, 2024